A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.

导出 LinkOut

翻译打印收藏纠错

作者： Stefanie,Fischer ^[1] ; Thorsten O,Götze ^[2] ; Aurelius,Omlin ^[1] ; Richard D,Baird ^[3] ; Keith M,Dawson ^[4] ; Christof,Zitt ^[4] ; Zita,Arany ^[4] ; Gaby,Tresch ^[4] ; Ulrike,Fiedler ^[4] ; Simone,Jeger ^[5] ; Samson,Fung ^[4] ; Philippe,Legenne ^[6] ; Nicolas,Leupin ^[4] ; Andreas,Schneeweiss ^[4] ; Carlo,Fremd ^[7]

作者单位： Kantonsspital St Gallen, Klinik für Medizinische Onkologie und Hämatologie, St Gallen, Switzerland. ^[1] Krankenhaus Nordwest GmbH, Institut für Klinisch-Onkologische Forschung, Frankfurt, Germany. ^[2] Cancer Research UK Cambridge Centre, Cambridge, United Kingdom. ^[3] Molecular Partners AG, Schlieren, Switzerland. ^[4] NBE-Therapeutics AG/Boehringer Ingelheim, Basel, Switzerland. ^[5] Fung Consulting, Eching, Germany. ^[6] National Center for Tumor Diseases (NCT), Heidelberg University Hospital and German Cancer Research Center, Heidelberg, Germany. ^[7]

主题词人类(Humans);女(雌)性(Female);乳腺肿瘤(Breast Neoplasms);抗肿瘤药(Antineoplastic Agents)

DOI 10.1200/PO.22.00006

PMID 36331248

发布时间 2022-11-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

JCO precision oncology

2022年6卷

e2200006页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.

JCO precision oncology

相似文献

JCO precision oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.

JCO precision oncology

相似文献

JCO precision oncology

相关期刊

检索历史清除